Overview

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Status:
Enrolling by invitation
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study. Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in the US, Europe, and Israel will initiate this study. Note: Approximately 30 centers overlap between MAVERICK and EXPLORER.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
MyoKardia, Inc.